GlassScriptPhysician profile
Matthew Buck
NPI 1518548098
$1,468.94
in general payments reported to CMS, 2019-2025
11 companies · $1,057 in 2025
The $1,057 reported for 2025 was more than what 88% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $412 · 2025: $1,057.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,283 · Travel and Lodging: $186.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,283.29 |
| Travel and Lodging | $185.65 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $340.84 | 2025 | Interstim |
| Boston Scientific Corporation | $320.45 | 2025 | Accolade Sr, General - Erectile Dysfunction |
| Olympus Corporation of The Americas | $209.60 | 2024 | Visiglide, Cysto-Nephro Videoscope |
| Coloplast Corp | $184.22 | 2025 | |
| Janssen Scientific Affairs, LLC | $141.29 | 2025 | Erleada |
| Angiodynamics, INC. | $120.62 | 2024 | Nanoknife |
| Janssen Biotech, INC. | $48.14 | 2025 | Erleada |
| 180 Medical, INC. | $29.56 | 2024 | |
| Sumitomo Pharma America, INC. | $28.56 | 2024 | Gemtesa |
| Corcept Therapeutics | $23.69 | 2024 | Korlym |
| Merck Sharp & Dohme LLC | $21.97 | 2025 | Lynparza |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Matthew Buck listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.